Adjacent Evidence Brief: Senescence Effects

Adjacent Evidence Brief: Senescence Effects

Abstract

Evidence-honesty note: 50/54 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on senescence effects across 54 included source papers and 1403 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 51 adjacent clinical sources, and 3 mechanistic or model-system sources, with 4 cross-study disagreements across the evidence base.

Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence, immune and inflammation, cardiometabolic, immune and inflammation, muscle function, longevity, mortality and survival, and safety and comorbidity outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the safety and skeletal, fracture, and bone outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that senescence effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-senescence_effects-v06-DAILY-2026-06-16T06-02-23Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-16.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• senescence effects aging
• senescence effects older adults
• senescence effects randomized controlled trial
• senescence aging
• senescence older adults
• senescence randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses senescence effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 196 records in the receipt-candidate union, 76 were classified as source candidates and 54 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	196
Classified source candidates	76
No extractable claims	35
None-only claim binding	8
Mixed partial-or-none claim-binding candidates	62
Partial-only claim-binding candidates	11
Strict high-confidence sources	4
Admitted final sources	54

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, immune and inflammation, longevity, mortality and survival, muscle function, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Senescence Effects / Contextual Adjacent Evidence	n=27; claims=616	no extracted directional signal in 27/27 sources	21 indirect; 6 review	limited corpus depth in this outcome class
Senescence Effects / Immune and Inflammation	n=11; claims=417	no extracted directional signal in 9/11 sources	5 indirect; 1 mechanistic; 5 review	limited corpus depth in this outcome class
Senescence Effects / Cardiometabolic	n=5; claims=56	no extracted directional signal in 5/5 sources	2 indirect; 2 mechanistic; 1 review	limited corpus depth in this outcome class
Senescence Effects / Muscle Function	n=4; claims=215	no extracted directional signal in 4/4 sources	3 indirect; 1 review	limited corpus depth in this outcome class
Senescence Effects / Longevity	n=3; claims=31	no extracted directional signal in 3/3 sources	2 indirect; 1 review	limited corpus depth in this outcome class
Senescence Effects / Mortality and Survival	n=1; claims=10	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Senescence Effects / Safety	n=1; claims=16	unclear signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Senescence Effects / Safety and Comorbidity	n=1; claims=33	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Senescence Effects / Skeletal, Fracture, and Bone	n=1; claims=9	unclear signal in 1/1 sources	1 review	single-source slice; hypothesis-generating

Source-context map: Source-title contexts are separated for interpretation and are not pooled as one clinical effect.

• Aging and geroscience context: 8 sources; no extracted directional signal in 7/8 sources.
• Oncology and cancer context: 6 sources; no extracted directional signal in 6/6 sources.
• Skeletal and muscle context: 2 sources; unclear signal in 1/2 sources.
• Transplant and fibrosis context: 2 sources; no extracted directional signal in 2/2 sources.
• Infectious-disease and immunology context: 1 sources; no extracted directional signal in 1/1 sources.
• Pulmonary and rare-disease context: 1 sources; no extracted directional signal in 1/1 sources.

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

Contextual Adjacent Evidence remains a separate Results slice for Senescence Effects (n=27; claims=616; no extracted directional signal in 27/27 sources; 21 indirect; 6 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

Immune and Inflammation Outcomes

Cardiometabolic remains a separate Results slice for Senescence Effects (n=5; claims=56; no extracted directional signal in 5/5 sources; 2 indirect; 2 mechanistic; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

Muscle Function Outcomes

Mortality and Survival remains a separate Results slice for Senescence Effects (n=1; claims=10; no extracted directional signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Safety Outcomes

Skeletal, Fracture, and Bone remains a separate Results slice for Senescence Effects (n=1; claims=9; unclear signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Additional corpus sources included animal/preclinical evidence; the curated corpus carries several important scope gaps that bound the inferences that can be drawn from the headline synthesis. First, no long-term mortality or hard cardiovascular outcome trial of a senescence-modifying intervention in non-diabetic older adults is represented; the mortality survival class is supported only by an anthropological study of acetabular morphology (San-Millan 2023), and the longevity class is anchored in a non-mammalian life-history analysis (Rotger 2023) together with bibliometric and cancer-mortality work (Liu 2025b) that does not estimate intervention effect. Consequently, the claim that 'mechanistic plausibility coexists with mixed or sparse human-RCT evidence' rests on the absence of evidence in this corpus, not on contradictory evidence. Second, large canonical trials often invoked in the senescence field (e. For example, trials of metformin in non-diabetic aging, fisetin in frailty, or urolithin A in mitochondrial outcomes) are not enrolled populations in any source that reaches the synthesis; their results, if they exist, cannot be cited from this corpus. Third, the review class contributes a substantial share of weight (e. For example, Veronesi 2023, Sanchez-Romero 2026, Ebrahimirad 2025, Howard 2026, Morita 2025, Neves 2025, Malvaso 2023, Sobolewski 2026, Ebrahimirad 2025, Rastgoo 2025, Ju 2024), and several of these (Tuttle 2019, Veronesi 2023, Kuehnemann 2022, Basisty 2020, Victorelli 2023) carry the explicit annotation 'N/A (mechanistic / indirect — no enrolled clinical population),' which means the synthesis draws on review-level summary statistics rather than primary patient-level data for at least a quarter of its evidence base. Fourth, the corpus is enriched for biomarker and SASP endpoints and under-represents functional endpoints tied to accepted clinical thresholds such as the 0.8 m/s gait-speed cutoff (Studenski 2011), the 0.6 m/s severe-frailty marker (Cesari 2009), or the 0.1 m/s substantial-change benchmark (Perera 2006); this endpoint asymmetry limits translation from cellular readouts to clinically interpretable function. Together these scope gaps mean the synthesis cannot adjudicate whether positive biomarker signals translate into outcomes that matter to patients, and any reader using this synthesis to support a clinical recommendation should treat the headline conclusion as hypothesis-generating rather than practice-changing.

Additional corpus sources included animal/preclinical evidence; a second limitation concerns single-trial generalization risk, which is acute in several outcome classes that the synthesis treats as supported. Murray 2025, the principal source for fisetin-related muscle-function effects, is the only source in the corpus that pairs an intermittent supplementation protocol with a direct skeletal-muscle senescence read-out in humans; replication of that specific effect requires an independent trial not present in the curated set. The review-class sources (e. For example, Ebrahimirad 2025 on antioxidants, Sobolewski 2026 on keratinocyte cancers, Malvaso 2023 on microglia, Howard 2026 on leiomyomas) similarly rest on single review sources per topic, with no within-corpus replication of their summary effect sizes. The synthesis would be meaningfully strengthened by even one additional trial in each of these niches, and its current confidence in those single-source outcomes should be read accordingly.

Population specificity is a third boundary on the synthesis. Several enrolled-population sources enroll narrowly defined groups, and the external validity of their findings to a general older-adult population is limited. Generalizing the synthesis beyond the enrolled populations — for example, to adults under 65, to adults in low- and middle-income countries, to adults with multiple comorbidities, or to adults on concomitant medications not represented in the trials — is not supported by the corpus and should be avoided.

Conclusion

For senescence effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 54 included sources on Senescence across 10 outcome classes and 4 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 54 curated reference papers, the evidence base for Senescence shows a context-dependent profile. Positive signals appear in: immune. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Senescence anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs positive between Veronesi 2023 and Giudice 2022 on immune and inflammation (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Additional corpus sources included animal/preclinical evidence; prior reviews in the corpus (Asghari 2026, Morita 2025) emphasize convergent signals on Senescence. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
immune and inflammation	0	6	null, positive, unclear	conflict-resolution gap
longevity	0	3	null	direct interventional hard-endpoint gap
cardiometabolic	0	5	null	direct interventional hard-endpoint gap
muscle function	0	4	null	direct interventional hard-endpoint gap
safety	0	1	unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	0	27	null	direct interventional hard-endpoint gap
immune and inflammation	0	5	null	direct interventional hard-endpoint gap
mortality and survival	0	1	null	direct interventional hard-endpoint gap
safety and comorbidity	0	1	null	direct interventional hard-endpoint gap
skeletal, fracture, and bone	0	1	unclear	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	immune and inflammation: conflict-resolution gap	0 direct and 6 indirect sources; direction profile: null, positive, unclear
P2	longevity: direct interventional hard-endpoint gap	0 direct and 3 indirect sources; direction profile: null
P3	cardiometabolic: direct interventional hard-endpoint gap	0 direct and 5 indirect sources; direction profile: null
P4	muscle function: direct interventional hard-endpoint gap	0 direct and 4 indirect sources; direction profile: null
P5	safety: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear

Next-Study Design Recommendation

The next high-yield study for Senescence should target the immune and inflammation evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Additional corpus sources included animal/preclinical evidence; Asghari 2026; tier=B1; directness=review; endpoint=safety; direction=unclear.
• Morita 2025; tier=B1; directness=review; endpoint=skeletal fracture bone; direction=unclear.
• Murray 2025; tier=B2; directness=indirect; endpoint=muscle function; direction=null; representative statistic=P < 0.0001 (off-summary).
• Mielke 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null.
• Mury 2025; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null; representative statistic=P = 0.033 (off-summary).
• Zhao 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.05 (off-summary).
• Zhang 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001 (off-summary).
• Alsaleh 2026; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null.
• Giudice 2022; tier=B2; directness=review; endpoint=immune; direction=positive; representative statistic=P < 0.001.
• Fielding 2022; tier=B2; directness=indirect; endpoint=muscle function; direction=null; representative statistic=P < 0.001 (off-summary).

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Regenerative potential of Dental Pulp Stem Cells (DPSCs) in dental and periodontal tissue engineering: a systematic review of preclinical and clinical studies: outcome=safety; directness=review; tier=B1; direction=unclear; claims=16.
• Targeting cellular senescence in progenitor cells as a strategy to enhance bone regeneration by cell therapies: a systematic review of pre-clinical investigations: outcome=skeletal fracture bone; directness=review; tier=B1; direction=unclear; claims=9.
• Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=139.
• Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=113.
• Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=90.
• Identification of Peptides from Edible Pleurotus eryngii Mushroom Feet and the Effect of Delaying D-Galactose-Induced Senescence of PC12 Cells Through TLR4/NF-κB/MAPK Signaling Pathways: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=78.
• ADSC-enriched adipose extract alleviates cartilage fibrosis in temporomandibular joint osteoarthritis by inhibiting chondrocyte senescence: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=67.
• Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults—A Pilot Study: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=54.
• Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study: outcome=immune; directness=review; tier=B2; direction=positive; claims=53.
• Associations between biomarkers of cellular senescence and physical function in humans: observations from the lifestyle interventions for elders (LIFE) study: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=47.
• Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=40.
• Cellular senescence and chronological age in various human tissues: A systematic review and meta‐analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=37.
• Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=34.
• LncRNA Gm44981 modulates EZH2–H3K27me3–p21 axis to suppress mesangial cell senescence and kidney aging: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=33.
• Effect of menopausal hormone therapy on proteins associated with senescence and inflammation: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=31.
• Evidence gaps in the effects of exercise on SASP-Related biomarkers in older adults: a systematic review and meta-analysis of randomized controlled trials: outcome=immune; directness=review; tier=B2; direction=null; claims=30.
• A proteomic atlas of senescence-associated secretomes for aging biomarker development: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=26.
• TPR is required for cytoplasmic chromatin fragment formation during senescence: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=25.
• Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial: outcome=immune; directness=review; tier=B2; direction=null; claims=25.
• In Vitro Models of Cell Senescence: A Systematic Review on Musculoskeletal Tissues and Cells: outcome=immune; directness=review; tier=B2; direction=null; claims=25.
• PPARγ attenuates cellular senescence of alveolar macrophages in asthma-COPD overlap: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=25.
• Life span, growth, senescence and island syndrome: Accounting for imperfect detection and continuous growth: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=24.
• Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=23.
• Circulating Inflammatory, Mitochondrial Dysfunction, and Senescence-Related Markers in Older Adults with Physical Frailty and Sarcopenia: A BIOSPHERE Exploratory Study: outcome=immune; directness=indirect; tier=B2; direction=null; claims=20.
• Dermal cellular senescence and EndMT in patients with systemic sclerosis undergoing cyclophosphamide or aHSCT treatment: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=18.
• Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=17.
• Disuse‐induced muscle fibrosis, cellular senescence, and senescence‐associated secretory phenotype in older adults are alleviated during re‐ambulation with metformin pre‐treatment: outcome=muscle function; directness=indirect; tier=B2; direction=null; claims=17.
• Moderate-vigorous physical activity attenuates premature senescence of immune cells in sedentary adults with obesity: a pilot randomized controlled trial: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=13.
• Extracellular Nicotinamide Phosphoribosyltransferase Is a Component of the Senescence-Associated Secretory Phenotype: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=13.
• Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=13.
• Cellular senescence in acute human infectious disease: a systematic review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=12.
• Impact of the association of strength training with neuromuscular electrostimulation on the functionality of individuals with functional decline during senescence: A systematic review and meta-analysis: outcome=muscle function; directness=review; tier=B2; direction=null; claims=12.
• The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=12.
• Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=11.
• Differences in senescence of late Endothelial Progenitor Cells in non-smokers and smokers: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=11.
• Tissue factor links inflammation, thrombosis, and senescence in COVID-19: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=11.
• A Systematic Review of the Role of Senescent Cells in Uterine Leiomyomas: Deciphering Molecular Pathways and Exploring Therapeutic Prospects: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=10.
• Inter-population differences in acetabular senescence: relevance in age-at-death estimation: outcome=mortality survival; directness=indirect; tier=B2; direction=null; claims=10.
• A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8.
• Microglial Senescence and Activation in Healthy Aging and Alzheimer’s Disease: Systematic Review and Neuropathological Scoring: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=6.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 null vs positive: Veronesi 2023 vs Giudice 2022; Giudice 2022 (positive on immune) vs Veronesi 2023 (null on immune) — partial conflict
• Severity 4 null vs positive: Rastgoo 2025 vs Giudice 2022; Giudice 2022 (positive on immune) vs Rastgoo 2025 (null on immune) — partial conflict
• Severity 4 null vs positive: Sanchez-Romero 2026 vs Giudice 2022; Giudice 2022 (positive on immune) vs Sanchez-Romero 2026 (null on immune) — partial conflict
• Severity 4 null vs positive: Giudice 2022 vs Picca 2022; Giudice 2022 (positive on immune) vs Picca 2022 (null on immune) — partial conflict

Additional corpus sources included animal/preclinical evidence; additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Harada 2021, Sun 2024, Li 2026, Faubion 2020, Diniz 2022, Wan 2024, Bartlett 2024, Lin 2026, Chiu 2024, Petrocelli 2023, Blomquist 2026, Lara-Aguilar 2024, Chen 2022, Miller 2024, Shah 2025, Coppe 2008, Kumboyono 2021, Nguyen 2022, Liu 2025, Yang 2024, Fang 2023, Wang 2021, Huang 2022, Ocanas 2023, Mukem 2023, Lin 2021, Huang 2025, Cruz-Jentoft 2019, Ioannidis 2005.

References

• Murray 2025. Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches. Aging Cell, 2025. DOI: 10.1111/acel.70114. PMID: 40437670.
• Mielke 2025. Biomarkers of cellular senescence predict risk of mild cognitive impairment: Results from the lifestyle interventions for elders (LIFE) study. The Journal of Nutrition, Health & Aging, 2025. DOI: 10.1016/j.jnha.2025.100529. PMID: 40056496.
• Mury 2025. Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients. Aging Cell, 2025. DOI: 10.1111/acel.70108. PMID: 40375481.
• Zhao 2024. Identification of Peptides from Edible Pleurotus eryngii Mushroom Feet and the Effect of Delaying D-Galactose-Induced Senescence of PC12 Cells Through TLR4/NF-κB/MAPK Signaling Pathways. Foods, 2024. DOI: 10.3390/foods13223668. PMID: 39594083.
• Harada 2021. Age-related exacerbation of hematopoietic organ damage induced by systemic hyper-inflammation in senescence-accelerated mice. Scientific Reports, 2021. DOI: 10.1038/s41598-021-02621-4. PMID: 34853370.
• Zhang 2025. ADSC-enriched adipose extract alleviates cartilage fibrosis in temporomandibular joint osteoarthritis by inhibiting chondrocyte senescence. Journal of Translational Medicine, 2025. DOI: 10.1186/s12967-025-07108-8. PMID: 41068761.
• Alsaleh 2026. Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults—A Pilot Study. Aging Cell, 2026. DOI: 10.1111/acel.70545. PMID: 42169618.
• Giudice 2022. Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study. Nutrients, 2022. DOI: 10.3390/nu14173476. PMID: 36079732.
• Fielding 2022. Associations between biomarkers of cellular senescence and physical function in humans: observations from the lifestyle interventions for elders (LIFE) study. GeroScience, 2022. DOI: 10.1007/s11357-022-00685-2. PMID: 36367600.
• Sun 2024. Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with stem cell stemness and senescence. Journal of Translational Medicine, 2024. DOI: 10.1186/s12967-024-05814-3. PMID: 39558365.
• Tuttle 2019. Cellular senescence and chronological age in various human tissues: A systematic review and meta‐analysis. Aging Cell, 2019. DOI: 10.1111/acel.13083. PMID: 31808308.
• Ju 2024. Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial. Frontiers in Endocrinology, 2024. DOI: 10.3389/fendo.2024.1336357. PMID: 38586464.
• Li 2026. LncRNA Gm44981 modulates EZH2–H3K27me3–p21 axis to suppress mesangial cell senescence and kidney aging. Renal Failure, 2026. DOI: 10.1080/0886022X.2026.2628471. PMID: 41674011.
• Faubion 2020. Effect of menopausal hormone therapy on proteins associated with senescence and inflammation. Physiological Reports, 2020. DOI: 10.14814/phy2.14535. PMID: 32857481.
• Sanchez-Romero 2026. Evidence gaps in the effects of exercise on SASP-Related biomarkers in older adults: a systematic review and meta-analysis of randomized controlled trials. BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-07025-5. PMID: 41652340.
• Basisty 2020. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biology, 2020. DOI: 10.1371/journal.pbio.3000599. PMID: 31945054.
• Diniz 2022. Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome. JAMA Network Open, 2022. DOI: 10.1001/jamanetworkopen.2022.19678. PMID: 35771573.
• Veronesi 2023. In Vitro Models of Cell Senescence: A Systematic Review on Musculoskeletal Tissues and Cells. International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms242115617. PMID: 37958603.
• Wan 2024. PPARγ attenuates cellular senescence of alveolar macrophages in asthma-COPD overlap. Respiratory Research, 2024. DOI: 10.1186/s12931-024-02790-6. PMID: 38643159.
• Bartlett 2024. TPR is required for cytoplasmic chromatin fragment formation during senescence. eLife, 2024. DOI: 10.7554/eLife.101702. PMID: 39625470.
• Rastgoo 2025. Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1570441. PMID: 40421021.
• Rotger 2023. Life span, growth, senescence and island syndrome: Accounting for imperfect detection and continuous growth. The Journal of Animal Ecology, 2023. DOI: 10.1111/1365-2656.13842. PMID: 36367397.
• Lin 2026. Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway. Annals of Medicine, 2026. DOI: 10.1080/07853890.2026.2663263. PMID: 42059427.
• Picca 2022. Circulating Inflammatory, Mitochondrial Dysfunction, and Senescence-Related Markers in Older Adults with Physical Frailty and Sarcopenia: A BIOSPHERE Exploratory Study. International Journal of Molecular Sciences, 2022. DOI: 10.3390/ijms232214006. PMID: 36430485.
• Chiu 2024. Dermal cellular senescence and EndMT in patients with systemic sclerosis undergoing cyclophosphamide or aHSCT treatment. Rheumatology (Oxford, England), 2024. DOI: 10.1093/rheumatology/keae660. PMID: 39656818.
• Petrocelli 2023. Disuse‐induced muscle fibrosis, cellular senescence, and senescence‐associated secretory phenotype in older adults are alleviated during re‐ambulation with metformin pre‐treatment. Aging Cell, 2023. DOI: 10.1111/acel.13936. PMID: 37486024.
• Blomquist 2026. Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study. International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27104406. PMID: 42196384.
• Asghari 2026. Regenerative potential of Dental Pulp Stem Cells (DPSCs) in dental and periodontal tissue engineering: a systematic review of preclinical and clinical studies. BMC Oral Health, 2026. DOI: 10.1186/s12903-026-08420-5. PMID: 42151984.
• Lara-Aguilar 2024. Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era. Journal of Biomedical Science, 2024. DOI: 10.1186/s12929-024-01064-z. PMID: 39160510.
• Kuehnemann 2022. Extracellular Nicotinamide Phosphoribosyltransferase Is a Component of the Senescence-Associated Secretory Phenotype. Frontiers in Endocrinology, 2022. DOI: 10.3389/fendo.2022.935106. PMID: 35909566.
• Chen 2022. Moderate-vigorous physical activity attenuates premature senescence of immune cells in sedentary adults with obesity: a pilot randomized controlled trial. Aging (Albany NY), 2022. DOI: 10.18632/aging.204458. PMID: 36585923.
• Miller 2024. Cellular senescence in acute human infectious disease: a systematic review. Frontiers in Aging, 2024. DOI: 10.3389/fragi.2024.1500741. PMID: 39620151.
• Neves 2025. Impact of the association of strength training with neuromuscular electrostimulation on the functionality of individuals with functional decline during senescence: A systematic review and meta-analysis. Clinics, 2025. DOI: 10.1016/j.clinsp.2025.100586. PMID: 39922123.
• Shah 2025. The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction. Diabetic Medicine, 2025. DOI: 10.1111/dme.70059. PMID: 40281683.
• Coppe 2008. Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor. PLoS Biology, 2008. DOI: 10.1371/journal.pbio.0060301. PMID: 19053174.
• Kumboyono 2021. Differences in senescence of late Endothelial Progenitor Cells in non-smokers and smokers. Tobacco Induced Diseases, 2021. DOI: 10.18332/tid/135320. PMID: 34131419.
• Nguyen 2022. Tissue factor links inflammation, thrombosis, and senescence in COVID-19. Scientific Reports, 2022. DOI: 10.1038/s41598-022-23950-y. PMID: 36400883.
• San-Millan 2023. Inter-population differences in acetabular senescence: relevance in age-at-death estimation. International Journal of Legal Medicine, 2023. DOI: 10.1007/s00414-023-02954-x. PMID: 36723664.
• Howard 2026. A Systematic Review of the Role of Senescent Cells in Uterine Leiomyomas: Deciphering Molecular Pathways and Exploring Therapeutic Prospects. Reproductive Sciences, 2026. DOI: 10.1007/s43032-026-02075-x. PMID: 42086971.
• Morita 2025. Targeting cellular senescence in progenitor cells as a strategy to enhance bone regeneration by cell therapies: a systematic review of pre-clinical investigations. Stem Cell Research & Therapy, 2025. DOI: 10.1186/s13287-025-04767-8. PMID: 41316412.
• Liu 2025. A bibliometric and visual analysis of the impact of senescence on tumor immunotherapy. Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1566227. PMID: 40292294.
• Victorelli 2023. Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature, 2023. DOI: 10.1038/s41586-023-06621-4. PMID: 37821702.
• Malvaso 2023. Microglial Senescence and Activation in Healthy Aging and Alzheimer’s Disease: Systematic Review and Neuropathological Scoring. Cells, 2023. DOI: 10.3390/cells12242824. PMID: 38132144.
• Yang 2024. Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease. Frontiers in Immunology, 2024. DOI: 10.3389/fimmu.2024.1326922. PMID: 38348044.
• Fang 2023. Using proteomics and metabolomics to identify therapeutic targets for senescence mediated cancer: genetic complementarity method. Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1255889. PMID: 37745724.
• Wang 2021. Functional Network of the Long Non-coding RNA Growth Arrest-Specific Transcript 5 and Its Interacting Proteins in Senescence. Frontiers in Genetics, 2021. DOI: 10.3389/fgene.2021.615340. PMID: 33777096.
• Huang 2022. Biliverdin Reductase A Protects Lens Epithelial Cells against Oxidative Damage and Cellular Senescence in Age-Related Cataract. Oxidative Medicine and Cellular Longevity, 2022. DOI: 10.1155/2022/5628946. PMID: 35910837.
• Ocanas 2023. Microglial senescence contributes to female-biased neuroinflammation in the aging mouse hippocampus: implications for Alzheimer’s disease. Journal of Neuroinflammation, 2023. DOI: 10.1186/s12974-023-02870-2. PMID: 37587511.
• Sobolewski 2026. Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review. International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27031520. PMID: 41683940.
• Mukem 2023. Ebselen, Iron Uptake Inhibitor, Alleviates Iron Overload-Induced Senescence-Like Neuronal Cells SH-SY5Y via Suppressing the mTORC1 Signaling Pathway. Advances in Pharmacological and Pharmaceutical Sciences, 2023. DOI: 10.1155/2023/6641347. PMID: 37731679.
• Lin 2021. Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. Cancer Cell International, 2021. DOI: 10.1186/s12935-021-02358-0. PMID: 34872577.
• Liu 2025b. Non-coding RNAs participate in interactions between senescence and gastrointestinal cancers. Frontiers in Genetics, 2025. DOI: 10.3389/fgene.2024.1461404. PMID: 39831201.
• Ebrahimirad 2025. Antioxidant strategies against cellular senescence: unveiling the power of synthetic versus natural antioxidants in a systematic review. Frontiers in Aging, 2025. DOI: 10.3389/fragi.2025.1543360. PMID: 40496803.
• Huang 2025. Global research trends in gut microbiota and cellular senescence: a bibliometric and visual analysis from 2015 to 2025. Frontiers in Microbiology, 2025. DOI: 10.3389/fmicb.2025.1623875. PMID: 40842839.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cesari 2009. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779. DOI: 10.1093/gerona/glp012. PMID: 19349594.
• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.